Online skin self-exam program for melanoma survivors
Official title: A Digital Intervention to Improve Skin Self-examination Among Melanoma Survivors
Run by Rutgers, The State University of New Jersey · NCT05373823 · Data updated 2026-11-12
This study is testing a new online program to help melanoma survivors do better skin self-exams and see if it works better than just reading an educational webpage.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 385 (estimated) |
| Sponsor | Rutgers, The State University of New Jersey Academic / other |
| Locations | 1 site (New Brunswick, New Jersey) |
| Status | Recruiting |
| Started | March 6, 2023 |
| Main results expected | December 31, 2026 |
| Study ends | March 31, 2027 |
| Registry record updated | July 28, 2026 |
| Trial ID | NCT05373823 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are melanoma survivors aged 18 and older, who are 3 to 5 years post-surgery, have no current evidence of cancer, and are not adherent to thorough skin self-examinations.
✕Probably not a fit
Patients who are currently undergoing treatment for melanoma or have evidence of active cancer may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project, mySmartSkin, is designed to improve skin self-examination practices among melanoma survivors through a hybrid effectiveness-implementation approach. It involves enhancing the existing mySmartSkin program by collaborating with stakeholders to gather insights and conduct usability testing. The study will then evaluate the effectiveness of this enhanced program in a randomized control trial, comparing it to an educational webpage, while also assessing implementation outcomes to facilitate future dissemination. The trial aims to engage multiple stakeholders and identify factors critical for scaling up the intervention in community and healthcare settings.
Why it matters
Potential benefit: If successful, this program could significantly improve early detection of new or recurrent melanomas among survivors.
How similar studies have gone: Other studies have shown promise in enhancing self-examination practices among cancer survivors, indicating that this approach may be effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of primary pathologic stage 0-III cutaneous malignant melanoma * Three months to five years post-surgery * No current evidence of cancer * Not adherent to thorough SSE (i.e., did not check entire body at least once during the past three months) * ≥ 18 years old * Internet access * Able to speak/read English * Able to provide informed consent Exclusion Criteria: * Children
Where it's running
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States Recruiting
Study contacts
- Principal investigator: Sharon Manne, PhD — Rutgers Cancer Institute of New Jersey
- Study coordinator: Sharon Manne, PhD
- Email: mannesl@cinj.rutgers.edu
- Phone: 732-235-6759
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Melanoma treatment with immunotherapy guided by serial ctDNA testing
This trial tests whether regular ctDNA blood tests during treatment can help tailor the plan for patients with advanced melanoma receiving nivolumab and ipilimumab.
-
Non-invasive skin-tape test to detect melanoma using methylation biomarkers
A non-invasive skin-tape test is being tried to see if it can detect melanoma in people who are about to have a biopsy for a suspicious pigmented lesion.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
BL-M08D treatment in melanoma and other solid tumors
A phase Ib/II study tests BL-M08D1 injections in adults with locally advanced or metastatic melanoma and other solid tumors to see if it is safe and helpful.
-
Aggressive lipid lowering in melanoma patients starting immune checkpoint therapy
This trial tests whether lowering cholesterol aggressively can reduce heart artery disease risk in melanoma patients who are just beginning immune checkpoint therapy.
-
Timing of Immunotherapy in Melanoma
This trial tests whether starting standard melanoma immunotherapy earlier in the day (before 10 am) versus later in the day (after 1 pm) makes a difference for patients with unresectable or metastatic melanoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.